REHOVOT, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2016 and provided a corporate update.
“Throughout the third quarter we continued to execute our strategic development plans for multiple product candidates within our portfolio, and are well positioned to achieve several key milestones by the end of 2016, including completion of clinical trial 006 and issuing the results of trial 101 with our Parkinson’s disease product candidates ND0612H and ND0701, respectively,” said Oded Lieberman, PhD, CEO of NeuroDerm. “With additional ND0612H trial initiations planned for later this year or early next year, we expect to enter 2017 with significant momentum to realize our clinical and commercial development goals. In late October, 2016, we had an end of phase 2 meeting with the FDA to discuss our clinical development program. We anticipate providing an update on that meeting upon receiving the FDA’s formal feedback. We also remain on track to meet with EU authorities in January 2017.”
